Christopher Hocking
Impact in
-
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
-
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Papers in
-
- Renal cell carcinoma treatment 3
- Gastric Cancer Management and Outcomes 2
- Oncology 6
- Colorectal Cancer Treatments and Studies 5
- Co-authors
- Ganessan Kichenadasse (1 shared paper)Timothy Price (8 shared papers)Howard Gurney (2 shared papers)Toni K. Choueiri (3 shared papers)Burçin Şimşek (2 shared papers)Amishi Y. Shah (2 shared papers)Andrea B. Apolo (2 shared papers)Mauricio Burotto (2 shared papers)
- Journals
- Journal of Clinical Oncology (2 papers)The Medical Journal of Australia (2 papers)BMJ Open (1 paper)Physiological Measurement (1 paper)BMC Cancer (1 paper)
- Partner nations
- AustraliaUnited KingdomUnited States
In The Last Decade
Christopher Hocking
18 papers receiving 381 citations
Christopher Hocking's Hit Papers
Peers
Comparison fields: 5 of 69
- Pulmonary and Respiratory Medicine 171
- Oncology 133
- Cancer Research 65
- Hepatology 14
- Surgery 74
Countries citing papers authored by Christopher Hocking
This map shows the geographic impact of Christopher Hocking's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Hocking with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Hocking more than expected).
Fields of papers citing papers by Christopher Hocking
This network shows the impact of papers produced by Christopher Hocking. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Hocking. The network helps show where Christopher Hocking may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher Hocking, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial Hit paper breakdown → | 2022 | 192 |
| 2 | 2014 | 55 | |
| 3 | 2009 | 32 | |
| 4 | 2013 | 28 | |
| 5 | 2013 | 19 | |
| 6 | 2022 | 16 | |
| 7 | 2014 | 10 | |
| 8 | 2013 | 9 | |
| 9 | 2014 | 9 | |
| 10 | 2013 | 4 | |
| 11 | 2015 | 3 | |
| 12 | 2022 | 3 | |
| 13 | 2024 | 2 | |
| 14 | 2020 | 2 | |
| 15 | 2014 | 1 | |
| 16 | 2024 | 1 | |
| 17 | 2014 | 1 | |
| 18 | 2021 | 1 |
About Christopher Hocking
Christopher Hocking is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Pathology and Forensic Medicine and Epidemiology, having authored 18 papers that have together received 388 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (5 papers), Renal cell carcinoma treatment (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Genetic factors in colorectal cancer (2 papers), Gastric Cancer Management and Outcomes (2 papers), Multiple and Secondary Primary Cancers (1 paper), Ethics in medical practice (1 paper) and Nausea and vomiting management (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (171 citations), Oncology (133 citations), Cancer Research (65 citations), Hepatology (14 citations) and Surgery (74 citations). Christopher Hocking has collaborated with scholars based in Australia, United Kingdom and United States. Frequent co-authors include Ganessan Kichenadasse, Timothy Price, Howard Gurney, Toni K. Choueiri, Burçin Şimşek, Amishi Y. Shah, Andrea B. Apolo, Mauricio Burotto, Cristina Suárez and Alketa Hamzaj. Their work appears in journals such as Journal of Clinical Oncology, The Medical Journal of Australia, BMJ Open, Physiological Measurement and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.